|
1
|
Malkoski SP and Wang XJ: Two sides of the
story? Smad4 loss in pancreatic cancer versus head-and-neck cancer.
FEBS Lett. 586:1984–1992. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moustakas A, Souchelnytskyi S and Heldin
CH: Smad regulation in TGF-beta signal transduction. J Cell Sci.
114:4359–4369. 2001.PubMed/NCBI
|
|
3
|
Jones S, Zhang X, Parsons DW, et al: Core
signaling pathways in human pancreatic cancers revealed by global
genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar
|
|
4
|
Hahn SA, Schutte M, Hoque AT, et al: DPC4,
a candidate tumor suppressor gene at human chromosome 18q21.1.
Science. 271:350–353. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu F: SMAD4/DPC4 and pancreatic cancer
survival. Commentary re: M Tascilar et al, The SMAD4 protein and
prognosis of pancreatic ductal adenocarcinoma Clin Cancer Res 7:
4115–4121, 2001. Clin Cancer Res. 7:3853–3856. 2001.PubMed/NCBI
|
|
6
|
Hahn SA, Hoque AT, Moskaluk CA, et al:
Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer
Res. 56:490–494. 1996.PubMed/NCBI
|
|
7
|
Croce CM: Chromosome translocations and
human cancer. Cancer Res. 46:6019–6023. 1986.PubMed/NCBI
|
|
8
|
Testa JR: Chromosome translocations in
human cancer. Cell Growth Differ. 1:97–101. 1990.PubMed/NCBI
|
|
9
|
Nowell PC and Hungerford DA: Chromosome
studies on normal and leukemic human leukocytes. J Natl Cancer
Inst. 25:85–109. 1960.PubMed/NCBI
|
|
10
|
Rowley JD: Letter: A new consistent
chromosomal abnormality in chronic myelogenous leukaemia identified
by quinacrine fluorescence and Giemsa staining. Nature.
243:290–293. 1973. View
Article : Google Scholar
|
|
11
|
Kurzrock R, Kantarjian HM, Druker BJ and
Talpaz M: Philadelphia chromosome-positive leukemias: from basic
mechanisms to molecular therapeutics. Ann Intern Med. 138:819–830.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Melo JV: The molecular biology of chronic
myeloid leukaemia. Leukemia. 10:751–756. 1996.PubMed/NCBI
|
|
13
|
Talpaz M, Shah NP, Kantarjian H, et al:
Dasatinib in imatinib-resistant Philadelphia chromosome-positive
leukemias. N Engl J Med. 354:2531–2541. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Advani AS and Pendergast AM: Bcr-Abl
variants: biological and clinical aspects. Leuk Res. 26:713–720.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Le Gendre O, Sookdeo A, Duliepre SA, Utter
M, Frias M and Foster DA: Suppression of AKT phosphorylation
restores rapamycin-based synthetic lethality in SMAD4-defective
pancreatic cancer cells. Mol Cancer Res. 11:474–481.
2013.PubMed/NCBI
|
|
16
|
Blobe GC, Schiemann WP and Lodish HF: Role
of transforming growth factor beta in human disease. N Engl J Med.
342:1350–1358. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Massagué J, Blain SW and Lo RS: TGFbeta
signaling in growth control, cancer, and heritable disorders. Cell.
103:295–309. 2000.PubMed/NCBI
|
|
18
|
Miyaki M and Kuroki T: Role of Smad4
(DPC4) inactivation in human cancer. Biochem Biophys Res Commun.
306:799–804. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Osman B, Doller A, Akool el S, et al:
Rapamycin induces the TGFbeta1/Smad signaling cascade in renal
mesangial cells upstream of mTOR. Cell Signal. 21:1806–1817. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Song K, Wang H, Krebs TL and Danielpour D:
Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated
Smad3 activation. EMBO J. 25:58–69. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Azar R, Alard A, Susini C, Bousquet C and
Pyronnet S: 4E-BP1 is a target of Smad4 essential for
TGFbeta-mediated inhibition of cell proliferation. EMBO J.
28:3514–3522. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang H, Li G, Wu JJ, Wang L, Uhler M and
Simeone DM: Protein kinase A modulates transforming growth
factor-beta signaling through a direct interaction with Smad4
protein. J Biol Chem. 288:8737–8749. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wilentz RE, Su GH, Dai JL, et al:
Immunohistochemical labeling for dpc4 mirrors genetic status in
pancreatic adenocarcinomas : a new marker of DPC4 inactivation. Am
J Pathol. 156:37–43. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang G and Yang X: Smad4-mediated TGF-beta
signaling in tumorigenesis. Int J Biol Sci. 6:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
|
